TY - JOUR

T1 - Response to biologics during the first six months of therapy in biologic-naïve patients with psoriasis predicts risk of disease flares

T2 - A danish nationwide study

AU - Loft, Nikolai

AU - Egeberg, Alexander

AU - Rasmussen, Mads Kirchheiner

AU - Bryld, Lars Erik

AU - Nissen, Christoffer Valdemar

AU - Dam, Tomas Norman

AU - Ajgeiy, Kawa Khaled

AU - Iversen, Lars

AU - Skov, Lone

N1 - Funding Information: The DERMBIO registry has entered into agreements with Abbvie, Eli Lilly, Almirall, UCB, Novartis, Janssen, and Leo Pharma. They receive post-marketing data and had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit. Conflicts of interest. NDL has been an honorary speaker for Eli Lilly and Janssen Cilag. AE has received research funding from Pfizer, Eli Lilly, Novartis, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Samsung Bioepis Co., Ltd, Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, BristolMyers Squibb, and Janssen Pharmaceuticals. MKR has been a paid speaker for AbbVie, Almirall, and LEO Pharma. Consulting, or serving on expert/advisory boards with AbbVie, Almirall, Janssen Cilag, and Eli Lilly. He served as investigator for Janssen Cilag, and Novartis. CVN has served on an advisory board for Almirall and received educational grants from AbbVie and Janssen. TND has been a paid speaker for Janssen Cilag and has been a consultant or has served on Advisory Boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly and LEO Pharma. LI has been a paid speaker for MSD, Pfizer, AbbVie, Almirall, Janssen Cilag, Eli Lilly, Novartis, LEO Pharma, Samsung and UCB. Consulting or serving on expert/advisory boards with Pfizer, AbbVie, Almirall, BMS, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma and MSD. Served as investigator for MSD, Pfizer, AbbVie, Janssen Cilag, Eli Lilly, Novartis, Amgen and LEO Pharma and received research and educational grant from Pfizer, AbbVie, Novartis, MSD and Leo Pharma. LS has been a paid speaker for AbbVie, Eli Lilly, Novartis, and LEO Pharma, and has been a consultant or has served on Advisory Boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, UCB, Almirall, and Sanofi. She has served as an investigator for AbbVie, Sanofi, Janssen Cilag, Boehringer Ingelheim, AstraZenica, Eli Lilly, Novartis, Regeneron, and LEO Pharma, and has received research and educational grants from Novartis, Sanofi, Janssen Cilag, and LEO Pharma. Funding Information: The DERMBIO registry has entered into agreements with Abbvie, Eli Lilly, Almirall, UCB, Novartis, Janssen, and Leo Pharma. They receive post-marketing data and had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit. Conflicts of interest. NDL has been an honorary speaker for Eli Lilly and Janssen Cilag. AE has received research funding from Pfizer, Eli Lilly, Novartis, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Samsung Bioepis Co., Ltd, Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals. MKR has been a paid speaker for AbbVie, Almirall, and LEO Pharma. Consulting, or serving on expert/advisory boards with AbbVie, Almirall, Janssen Cilag, and Eli Lilly. He served as investigator for Janssen Cilag, and Novartis. CVN has served on an advisory board for Almirall and received educational grants from AbbVie and Janssen. TND has been a paid speaker for Janssen Cilag and has been a consultant or has served on Advisory Boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly and LEO Pharma. LI has been a paid speaker for MSD, Pfizer, AbbVie, Almirall, Janssen Cilag, Eli Lilly, Novartis, LEO Pharma, Samsung and UCB. Consulting or serving on expert/advisory boards with Pfizer, AbbVie, Almirall, BMS, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma and MSD. Served as investigator for MSD, Pfizer, AbbVie, Janssen Cilag, Eli Lilly, Novartis, Amgen and LEO Pharma and received research and educational grant from Pfizer, AbbVie, Novartis, MSD and Leo Pharma. LS has been a paid speaker for AbbVie, Eli Lilly, Novartis, and LEO Pharma, and has been a consultant or has served on Advisory Boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, UCB, Almirall, and Sanofi. She has served as an investigator for AbbVie, Sanofi, Janssen Cilag, Boehringer Ingelheim, AstraZenica, Eli Lilly, Novartis, Regeneron, and LEO Pharma, and has received research and educational grants from Novartis, Sanofi, Janssen Cilag, and LEO Pharma. Publisher Copyright: © 2021, Medical Journals/Acta D-V. All rights reserved.

PY - 2021

Y1 - 2021

N2 - Early response to treatment with biologics might be important for the stability of psoriasis and long-term outcome. The aim of this study was therefore to assess whether risk of flares and drug survival are associated with disease activity in the first 6 months of treatment of psoriasis with biologics. Biologic-naïve patients from the Danish nationwide registry, DERMBIO, were grouped based on absolute Psoriasis Area and Severity Index (PASI) during the first 6 months of treatment, as: PASI = 0, PASI > 0–≤2, PASI > 2–≤ 4, and PASI > 4. Among 1,684 patients, 746 achieved PASI= 0, 485 PASI > 0–≤2, 246 PASI > 2–≤4, and 207 PASI > 4. Longer flare-free period and drug survival were observed for patients with lower PASI in the first 6 months of treatment (adjusted hazard ratios for flares (95% confidence interval) with PASI= 0 as reference: PASI > 0–≤2 (1.35 (1.11–1.72]), PASI > 2–≤ 4 (2.32 [1.80–2.99]), and PASI > 4 (2.38 [1.80–3.15])). In conclusion, a low PASI in the first 6 months of treatment with biologics in biologic-naïve patients with psoriasis was associated with a more stable disease course, lower risk of flares, and longer drug survival.

AB - Early response to treatment with biologics might be important for the stability of psoriasis and long-term outcome. The aim of this study was therefore to assess whether risk of flares and drug survival are associated with disease activity in the first 6 months of treatment of psoriasis with biologics. Biologic-naïve patients from the Danish nationwide registry, DERMBIO, were grouped based on absolute Psoriasis Area and Severity Index (PASI) during the first 6 months of treatment, as: PASI = 0, PASI > 0–≤2, PASI > 2–≤ 4, and PASI > 4. Among 1,684 patients, 746 achieved PASI= 0, 485 PASI > 0–≤2, 246 PASI > 2–≤4, and 207 PASI > 4. Longer flare-free period and drug survival were observed for patients with lower PASI in the first 6 months of treatment (adjusted hazard ratios for flares (95% confidence interval) with PASI= 0 as reference: PASI > 0–≤2 (1.35 (1.11–1.72]), PASI > 2–≤ 4 (2.32 [1.80–2.99]), and PASI > 4 (2.38 [1.80–3.15])). In conclusion, a low PASI in the first 6 months of treatment with biologics in biologic-naïve patients with psoriasis was associated with a more stable disease course, lower risk of flares, and longer drug survival.

KW - Biologics

KW - Drug survival

KW - Flares

KW - PASI90PASI100

KW - Psoriasis

U2 - 10.2340/00015555-3722

DO - 10.2340/00015555-3722

M3 - Journal article

C2 - 33320277

AN - SCOPUS:85099326675

VL - 101

SP - 1

EP - 7

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 1

M1 - adv00357

ER -